Patents by Inventor Erik Henke

Erik Henke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide-conjugated oligonucleotide therapeutic and method of making and using same
    Patent number: 9393317
    Abstract: Conjugates for the efficient delivery of sequence-specific antisense to cells of a selected type for the inhibition of a target protein have the general formula: peptide-HBL-antisense in which the peptide is a homing peptide which directs the conjugate to cells of a particular type, antisense is an antisense oligonucleotide having a sequence selected to provide sequence-specific inhibition of the target protein, and HBL is a heterobifunctional linker having reactivity towards amino and sulfhydryl groups.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: July 19, 2016
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Robert Benezra, Erik Henke
  • Peptide-Conjugated Oligonucleotide Therapeutic and Method of Making and Using Same
    Publication number: 20150087599
    Abstract: Conjugates for the efficient delivery of sequence-specific antisense to cells of a selected type for the inhibition of a target protein have the general formula: peptide-HBL-antisense in which the peptide is a homing peptide which directs the conjugate to cells of a particular type, antisense is an antisense oligonucleotide having a sequence selected to provide sequence-specific inhibition of the target protein, and HBL is a heterobifunctional linker having reactivity towards amino and sulfhydryl groups.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 26, 2015
    Inventors: Robert Benezra, Erik Henke
  • Peptide-conjugated oligonucleotide therapeutic and method of making and using same
    Patent number: 8895701
    Abstract: Conjugates for the efficient delivery of sequence-specific antisense to cells of a selected type for the inhibition of a target protein have the general formula: peptide-HBL-antisense in which the peptide is a homing peptide which directs the conjugate to cells of a particular type, antisense is an antisense oligonucleotide having a sequence selected to provide sequence-specific inhibition of the target protein, and HBL is a heterobifunctional linker having reactivity towards amino and sulfhydryl groups.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: November 25, 2014
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Robert Benezra, Erik Henke
  • Peptide-Conjugated Oligonucleotide Therapeutic and Method of Making and Using Same
    Publication number: 20110003754
    Abstract: Conjugates for the efficient delivery of sequence-specific antisense to cells of a selected type for the inhibition of a target protein have the general formula: peptide-HBL-antisense in which the peptide is a homing peptide which directs the conjugate to cells of a particular type, antisense is an antisense oligonucleotide having a sequence selected to provide sequence-specific inhibition of the target protein, and HBL is a heterobifunctional linker having reactivity towards amino and sulfhydryl groups.
    Type: Application
    Filed: July 2, 2010
    Publication date: January 6, 2011
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Robert Benezra, Erik Henke
  • EPOTHILONE SYNTHESIS BUILDING BLOCKS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHODS FOR THEIR PRODUCTION AND METHODS FOR THE PRODUCTION OF EPOTHILONES B, D AND EPOTHILONE DERIVATIVES
    Patent number: 6867333
    Abstract: The present invention is directed to novel acyloins, their derivatives, methods for their production and their use for the production of novel epothilones and their derivatives. In addition, the invention is directed to the building blocks for epothilone synthesis, methods for their production and the use of synthetic building blocks for the production of epothilones and their derivatives.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: March 15, 2005
    Assignee: Morphochem AG
    Inventors: Ludger A. Wessjohann, Gunther Scheid, Uwe Bornscheuer, Erik Henke, Wouter Kuit, Romano Orru
  • Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives
    Publication number: 20040082651
    Abstract: The present invention is directed to novel acyloins, their derivatives, methods for their production and their use for the production of novel epothilones and their derivatives. In addition, the invention is directed to the building blocks for epothilone synthesis, methods for their production and the use of synthetic building blocks for the production of epothilones and their derivatives.
    Type: Application
    Filed: April 15, 2003
    Publication date: April 29, 2004
    Inventors: Ludger A. Wessjohann, Gunther Scheid, Uwe Bornscheuer, Erik Henke, Wouter Kuit, Romano Orru
  • Process for preparation to stereoisomeric carboxylic acid esters
    Patent number: 6365398
    Abstract: The present invention relates to a process for the preparation of stereoisomeric carboxylic acid esters consisting of an acid and of an alcohol component each having at least one chiral center, at least one stereoisomer of the carboxylic acid ester being present in an excess, by reacting a racemic carboxylic acid ester with a racemic alcohol in the presence of a carboxyl ester hydrolase (EC 3.1.1).
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: April 2, 2002
    Assignee: BASF Aktiengesellschaft
    Inventors: Uwe Bornscheuer, Erik Henke, Hong Yang
  • Process for the resolution of esters of arylalkylcarboxylic acids
    Patent number: 6201147
    Abstract: The invention relates to a process for the resolution of esters of arylalkylcarboxylic acids of the general formula which comprises reacting compounds of the general formula I with an alcohol of the general formula R6—OH in the presence of a lipase or esterase to give compounds of the general formulae Ia and II at least one of the compounds of the formulae Ia and II being present in an enantiomeric excess and the substituents and variables in the formulae I, Ia and II are as defined in the specification.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: March 13, 2001
    Assignee: BASF Aktiengesellschaft
    Inventors: Uwe Bornscheuer, Erik Henke, Yang Hong